AGOMAB
Live / Registered — Registered (as of 07 Oct 2025)
What this means for you
Registered since 07 Oct 2025. The owner can stop confusingly similar uses in the classes it covers.
Record
- Serial number
- 79408296
- Registration number
- 7971578
- Mark type
- Stylized text
- Filed
- 18 Sept 2024
- Published for opposition
- 19 Aug 2025
- Registered
- 07 Oct 2025
- Attorney of record
- Thomas A. Polcyn
Goods and services
- Class 005 — Pharmaceuticals: Pharmaceutical and medical preparations for the treatment of fibrosis, fibrotic diseases, skin diseases, eye diseases, Lung diseases, Idiopathic pulmonary fibrosis, Interstitial lung disease, progressive pulmonary fibrosis, idiopathic pulmonary fibrosis, organ failure, liver disease, kidney disease, inflammatory disease, Inflammatory bowel disease, Crohn's disease, fibrostenosing Crohn's disease, Luminal Crohn's disease, Perianal Crohn's disease, Fistulizing Crohn's disease, ulcerative colitis, Intestinal cancer, Pulmonary arterial hypertension, degenerative disease, autoimmune disease, diseases requiring tissue repair; chemical preparations for medical and pharmaceutical purposes, namely, for fibrosis, fibrotic diseases, skin diseases, eye diseases, Lung diseases, Idiopathic pulmonary fibrosis, Interstitial lung disease, progressive pulmonary fibrosis, idiopathic pulmonary fibrosis, organ failure, liver disease, kidney disease, inflammatory disease, Inflammatory bowel disease, Crohn's disease, fibrostenosing Crohn's disease, Luminal Crohn's disease, Perianal Crohn's disease, Fistulizing Crohn's disease, ulcerative colitis, Intestinal cancer, Pulmonary arterial hypertension, degenerative disease, autoimmune disease, diseases requiring tissue repair; pharmaceutical and medical preparations for use in relation to treating fibrosis, fibrotic diseases, fibrostenosing Crohn's disease, idiopathic pulmonary fibrosis, skin diseases, eye diseases, organ failure, liver disease, kidney disease, inflammatory disease, degenerative disease, autoimmune disease, and the treatment of diseases requiring tissue repair; small molecule drugs, namely, medicinal preparations for fibrosis, fibrotic diseases, skin diseases, eye diseases, Lung diseases, Idiopathic pulmonary fibrosis, Interstitial lung disease, progressive pulmonary fibrosis, idiopathic pulmonary fibrosis, organ failure, liver disease, kidney disease, inflammatory disease, Inflammatory bowel disease, Crohn's disease, fibrostenosing Crohn's disease, Luminal Crohn's disease, Perianal Crohn's disease, Fistulizing Crohn's disease, ulcerative colitis, Intestinal cancer, Pulmonary arterial hypertension, degenerative disease, autoimmune disease, diseases requiring tissue repair; antibodies; pharmaceutical and medical preparations incorporating antibodies for the treatment of fibrosis, fibrotic diseases, skin diseases, eye diseases, Lung diseases, Idiopathic pulmonary fibrosis, Interstitial lung disease, progressive pulmonary fibrosis, idiopathic pulmonary fibrosis, organ failure, liver disease, kidney disease, inflammatory disease, Inflammatory bowel disease, Crohn's disease, fibrostenosing Crohn's disease, Luminal Crohn's disease, Perianal Crohn's disease, Fistulizing Crohn's disease, ulcerative colitis, Intestinal cancer, Pulmonary arterial hypertension, degenerative disease, autoimmune disease, diseases requiring tissue repair
- Class 042 — Scientific and technological services: Scientific research and development services; Scientific research in the nature of conducting clinical trials for others; research and development in the fields of fibrosis, fibrotic diseases, fibrostenosing Crohn's disease, idiopathic pulmonary fibrosis, skin diseases, eye diseases, organ failure, liver disease, kidney disease, inflammatory disease, degenerative disease, autoimmune disease, and the treatment of diseases requiring tissue repair; research and development in the fields of small molecules and antibodies; research, development and product design of pharmaceutical and medical preparations; pharmaceutical drug development and discovery services; laboratory and medical laboratory product research and development services; providing medical and scientific research information in the field of pharmaceuticals and clinical trials; consultancy, advisory and information services relating to all the aforesaid
Owner
Prosecution history
- 30 Mar 2026 — NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
- 29 Mar 2026 — NOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB
- 07 Jan 2026 — FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
- 07 Oct 2025 — NOTICE OF REGISTRATION CONFIRMATION EMAILED
- 07 Oct 2025 — REGISTERED-PRINCIPAL REGISTER
- 03 Oct 2025 — NOTICE OF REGISTRATION CONFIRMATION EMAILED
- 19 Aug 2025 — OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
- 19 Aug 2025 — PUBLISHED FOR OPPOSITION
- 13 Aug 2025 — NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
- 15 Jul 2025 — APPROVED FOR PUB - PRINCIPAL REGISTER
- 11 Jul 2025 — EXAMINER'S AMENDMENT ENTERED
- 11 Jul 2025 — NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
- 11 Jul 2025 — EXAMINERS AMENDMENT E-MAILED
- 11 Jul 2025 — EXAMINERS AMENDMENT -WRITTEN
- 03 Jul 2025 — TEAS/EMAIL CORRESPONDENCE ENTERED